Press Releases
-
Oct 9, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
Oct 7, 2019BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich BioMarin's pipeline, which drives...
-
Oct 1, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a fireside discussion at the...
-
Sep 26, 2019BMN 307 Represents a Potential 3rd PKU Treatment Option in BioMarin's PKU Franchise
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today announced that it has submitted a Clinical Trial Application...
-
Sep 9, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer and Henry Fuchs, M.D., President, Worldwide Research &...
-
Aug 28, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 17th Annual Global...
-
Aug 1, 2019- Total Revenues of $387.8 million in the Quarter
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2019 2018 % Change 2019 2018 % Change Total Revenues $ 387.8
-
Jul 16, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Jul 9, 2019
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of pharmaceutical veteran and former Johnson & Johnson...
-
Jul 8, 2019Potential 1st Marketing Application for a Gene Therapy Product in Any Type of Hemophilia to be Reviewed by Health Authorities
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that based on recent meetings with health authorities in the U.S. and Europe, the company plans to submit marketing applications to both...
-
Jun 26, 2019Abstract Covers Efficacy and Safety of AAV Gene Therapy Over 3 Years with Valoctocogene Roxaparvovec in Severe Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and principal investigator for...
-
Jun 21, 2019European Commission Approval Triggers $15 Million Payment
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company earned a $15 million milestone payment from Pfizer, Inc. This milestone payment was triggered by the European Commission...
-
Jun 18, 2019Company Announces Enrollment Met for 2-5 Year-Old Cohort in Separate Phase 2 Study in Infants and Young Children
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the New England Journal of Medicine (NEJM) published online today results from a Phase 2 dose-finding and extension study for vosoritide,...
-
Jun 5, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development, will present at the Goldman Sachs 40th Annual Global Healthcare...
-
Jun 4, 2019First and Only Treatment in China Approved for Patients with This Ultra-Rare Genetic Condition
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Vimizim® (elosulfase alfa) has been approved by the National Medical Products Administration (NMPA) for the treatment of patients...
-
May 28, 2019Timing of Regulatory Submissions to Be Determined in 3Q 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A achieved pre-specified clinical...
-
May 28, 2019Substantial Reduction in excess of 92% in Mean Bleed Rate Requiring Factor VIII Infusions; Sustained over the Period of Observation (3 Years in High Dose and 2 Years in Low Dose)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene...
-
May 27, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will host a conference call and webcast on Tuesday, May 28 at 8:00am ET to discuss program updates. Conference Call and...
-
May 16, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Robert Baffi, Ph.D., Executive Vice President, Technical Operations, will participate in a gene therapy manufacturing focused...
-
May 8, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care...
-
May 6, 2019First Enzyme Substitution Therapy Approved in Europe to Treat the Underlying Cause of PKU in Patients Aged 16 Years or Older at Doses up to 60 mg
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Commission (EC) has granted marketing authorization for Palynziq® (pegvaliase injection) at doses of up to 60 mg once...
-
Apr 25, 2019- Total Revenues Top $400 million in the Quarter
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2019 2018 % Change Total Revenues $ 400.7 $ 373.4 7% Net Product Revenues Marketed...
Apr 17, 2019Company Ranks 1st Among Midsize Employers in 'Drugs & Biotechnology' IndustryBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked fourth on Forbes magazine's 2019 list of "America's Best Midsize Employers," increasing from 51st on last year's...
-
Apr 2, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Mar 6, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Cowen and Company Health Care Conference on...
